Rhinitis, Allergic, Perennial
Conditions
Brief summary
Study to investigate the safety and efficacy information of Alesion® Tablet under the proper use in daily clinical practice after new treatment guideline for allergic rhinitis, bronchial asthma, eczema, dermatitis, urticaria, pruritus, prurigo and psoriasis vulgaris with itching
Interventions
DRUGAlesion®
Sponsors
Boehringer Ingelheim
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
All the patients who: * haven't treatment experience of epinastine product; * have at least one out of following diseases. allergic rhinitis, eczema, dermatitis, pruritus, prurigo, urticaria, psoriasis with itching, bronchial asthma
Exclusion criteria
* Alesion® Tablet is contraindicated for the patients with history of hypersensitivity to any ingredients of Alesion® Tablet in package insert. However, it is unknown whether a patient is hypersensitive to the ingredients of the product in almost cases. And this survey is drug utilization study to observe actual use in any patients. Therefore
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of adverse drug reactions | up to 24 months | classified by Medical Dictionary for Regulatory Activities (MedDRA) |
| Incidence of adverse drug reactions classified by patient's background/treatment factors | up to 24 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall assessment of efficacy by investigator on a 3-point scale | after 24 months |
Outcome results
None listed